GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Scaled Net Operating Assets

Oncopeptides AB (STU:OND) Scaled Net Operating Assets : -0.01 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oncopeptides AB's operating assets for the quarter that ended in Dec. 2024 was €5.71 Mil. Oncopeptides AB's operating liabilities for the quarter that ended in Dec. 2024 was €5.91 Mil. Oncopeptides AB's Total Assets for the quarter that ended in Sep. 2024 was €28.12 Mil. Therefore, Oncopeptides AB's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was -0.01.


Oncopeptides AB Scaled Net Operating Assets Historical Data

The historical data trend for Oncopeptides AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Scaled Net Operating Assets Chart

Oncopeptides AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -0.15 -0.09 0.02 -0.01

Oncopeptides AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - -0.38 0.01 -0.01

Competitive Comparison of Oncopeptides AB's Scaled Net Operating Assets

For the Biotechnology subindustry, Oncopeptides AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Scaled Net Operating Assets falls into.



Oncopeptides AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oncopeptides AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(5.708-5.913)/21.31
=-0.01

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=21.229 - 15.521
=5.708

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.51 - 10.597 - 0
=5.913

Oncopeptides AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(5.708-5.913)/28.117
=-0.01

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=21.229 - 15.521
=5.708

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.51 - 10.597 - 0
=5.913

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Industry
Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines